BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26248280)

  • 1. Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.
    Coutinho de Souza P; Mallory S; Smith N; Saunders D; Li XN; McNall-Knapp RY; Fung KM; Towner RA
    PLoS One; 2015; 10(8):e0134276. PubMed ID: 26248280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OKN-007 decreases tumor necrosis and tumor cell proliferation and increases apoptosis in a preclinical F98 rat glioma model.
    de Souza PC; Balasubramanian K; Njoku C; Smith N; Gillespie DL; Schwager A; Abdullah O; Ritchey JW; Fung KM; Saunders D; Jensen RL; Towner RA
    J Magn Reson Imaging; 2015 Dec; 42(6):1582-91. PubMed ID: 25920494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
    Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
    J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
    Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
    Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling.
    Zheng X; Gai X; Han S; Moser CD; Hu C; Shire AM; Floyd RA; Roberts LR
    Genes Chromosomes Cancer; 2013 Mar; 52(3):225-36. PubMed ID: 23109092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C
    Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
    Watanabe T; Ohtani T; Aihara M; Ishiuchi S
    J Neurosurg; 2013 Apr; 118(4):838-45. PubMed ID: 23311938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models.
    Kogiso M; Qi L; Braun FK; Injac SG; Zhang L; Du Y; Zhang H; Lin FY; Zhao S; Lindsay H; Su JM; Baxter PA; Adesina AM; Liao D; Qian MG; Berg S; Muscal JA; Li XN
    Clin Cancer Res; 2018 May; 24(9):2159-2170. PubMed ID: 29463553
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting nitric oxide and NMDA receptor-associated pathways in treatment of high grade glial tumors. Hypotheses for nitro-memantine and nitrones.
    Altinoz MA; Elmaci İ
    Nitric Oxide; 2018 Sep; 79():68-83. PubMed ID: 29030124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
    Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
    Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
    Kamoun WS; Ley CD; Farrar CT; Duyverman AM; Lahdenranta J; Lacorre DA; Batchelor TT; di Tomaso E; Duda DG; Munn LL; Fukumura D; Sorensen AG; Jain RK
    J Clin Oncol; 2009 May; 27(15):2542-52. PubMed ID: 19332720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
    Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW
    J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
    Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.
    Feng H; Li Y; Yin Y; Zhang W; Hou Y; Zhang L; Li Z; Xie B; Gao WQ; Sarkaria JN; Raizer JJ; James CD; Parsa AT; Hu B; Cheng SY
    Neuro Oncol; 2015 Jun; 17(6):832-42. PubMed ID: 25468898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory agent, OKN-007, reverses long-term neuroinflammatory responses in a rat encephalopathy model as assessed by multi-parametric MRI: implications for aging-associated neuroinflammation.
    Towner RA; Saunders D; Smith N; Gulej R; McKenzie T; Lawrence B; Morton KA
    Geroscience; 2019 Aug; 41(4):483-494. PubMed ID: 31478121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo.
    Denicolaï E; Baeza-Kallee N; Tchoghandjian A; Carré M; Colin C; Jiglaire CJ; Mercurio S; Beclin C; Figarella-Branger D
    Oncotarget; 2014 Nov; 5(21):10934-48. PubMed ID: 25400117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
    Paulsson J; Lindh MB; Jarvius M; Puputti M; Nistér M; Nupponen NN; Paulus W; Söderberg O; Dresemann G; von Deimling A; Joensuu H; Ostman A; Hasselblatt M
    Int J Cancer; 2011 Apr; 128(8):1981-8. PubMed ID: 20589679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.